Loading clinical trials...
Loading clinical trials...
A Randomized, Open-label, Two-arm Phase II Trial Comparing the Efficacy of Sequential Ipilimumab Versus Best Supportive Care Following First-line Chemotherapy in Subjects With Unresectable Locally Advanced/Metastatic Gastric or Gastro-esophageal Junction Cancer
The purpose of the study is to compare the efficacy of Ipilimumab and standard of care as sequential or maintenance treatment immediately after first-line chemotherapy in the treatment of unresectable or metastatic gastric and gastro-esophageal cancer.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Mount Sinai Medical Center
Miami Beach, Florida, United States
Nyu Clinical Cancer Center
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
The University Of Texas Md Anderson Cancer Center
Houston, Texas, United States
Local Institution
Montpellier, France
Local Institution
Nice, France
Local Institution
Rennes, France
Local Institution
Toulouse, France
Local Institution
Mainz, Germany
Local Institution
Hong Kong, Hong Kong
Start Date
July 1, 2012
Primary Completion Date
July 1, 2014
Completion Date
April 1, 2015
Last Updated
May 17, 2016
143
ACTUAL participants
Ipilimumab
BIOLOGICAL
Best Supportive care (BSC)
OTHER
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions